Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Long Term Therapy with Nebivolol in Patients with Hypertension

  • 8 Accesses

Summary

Nebivolol, a β1 -selective β-blocker, was studied over a period of 6 months in patients with hypertension. The purpose of the study was to determine the efficacy, dose range and tolerability of the drug.

42 patients with hypertension were recruited into the study. After a 4-week placebo run-in, patients received nebivolol 5, 7.5 or 10mg sequentially until normalisation of blood pressure was achieved. Blood pressure was measured (using a Hawksley random-zero sphygmomanometer) after 5 minutes in the supine position, and sitting.

Diastolic blood pressure normalised (⩽ 95mm Hg; p = < 0.01) in 37 patients (88%) on nebivolol 5mg. The 5 remaining patients did not respond to 5, 7.5 or 10mg doses.

Adverse effects occurred in 10 patients (23.8%) during the placebo run-in and in 7 patients (16.6%) during nebivolol treatment (p = NS).

Nebivolol was a safe and efficacious drug at the 5mg dose.

This is a preview of subscription content, log in to check access.

References

  1. Cobo C, De Cree J, Geukens H. Efectos Hemodinámicos del Nebivolol. Un bloqueador selectivo beta 1, comparado con propranolol, pindolol y atenolol. Archivos del Instituto de Cardiologia de Mexico 57: 452, 1987

  2. De Crée J, Cobo C, Geukens H. Comparison of the subacute hemodynamic effects of atenolol, propranolol, pindolol and nebivolol. Angiology 41: 95, 1990

  3. De Crée J, Franken P, Vandevivere J, Geukens H. Hemodynamic effects of nebivolol in men: comparison of radionuclide angiocardiography with systolic time intervals. Angiology 39: 526–534, 1988b

  4. De Crée J, Geukens H, Cobo C, Verhaegen H. Subacute hemodynamic effects of nebivolol in man at rest and during exercise. Angiology 38: 440–448, 1987

  5. De Crée J, Geukens H, Leempoels, Verhaegen H. Haemodynamic effects in man during exercise of a single oral dose of nebivolol (R67555), a new beta-1-adrenoceptor blocking agent. A comparative study with atenolol, pindolol and propranolol. Drug Development Research 8: 109–117, 1986

  6. De Crée J, Geukens H, Verhaegen H. Acute hemodynamic effects of 2 enantiomers of nebivolol (R67138 and 67145) in men at rest and during exercise. Clinical Research Report on R67555. 21, 1988a

  7. Van de Water A, Janssens W, Van Nueten J, Xhonneux R, De Crée J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent and selective beta 1-adrenergic antagonist. Journal of Cardiovascular Pharmacology 11: 552–563, 1988

  8. Van Glabbeek A, Wouters L, Xhonneux R. Electrophysiological data of R67555 (nebivolol). Preclinical Research Report 6: 1987

Download references

Author information

Correspondence to Dr Carlos Cobo.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cobo, C., Alcocer, L. Long Term Therapy with Nebivolol in Patients with Hypertension. Drug Invest 3, 180–182 (1991). https://doi.org/10.1007/BF03258298

Download citation

Keywords

  • Atenolol
  • Pindolol
  • Nebivolol
  • Cobo
  • Systolic Time Interval